Latest News for: refractory

Edit

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma (Form 6-K) (HUTCHMED (China) Ltd)

Public Technologies 21 Mar 2025
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma.
Edit

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Pharmiweb 21 Mar 2025
TAZVERIK® is approved in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive FL (only when standard treatment is not applicable).
Edit

Refractory Metastatic Melanoma Pipeline Report 2025, with Focus on BioNTech SE, Y-mAbs and Therapeutics Seagen

Nasdaq Globe Newswire 20 Mar 2025
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering ... Refractory Metastatic Melanoma Emerging Drugs Chapters.
Edit

Muscat Eye Laser Center: Redefining the future of Ophthalmology

Muskat Daily 20 Mar 2025
In the heart of Oman, Muscat Eye Laser Center (MELC) stands as the undisputed leader in ophthalmology, combining cutting-edge technology with world-class patient care ... Founded in 2002 by visionary businessman Mr ... A World-Class Team of Experts ... Dr ... Dr ... Dr.
Edit

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory ...

Nasdaq Globe Newswire 17 Mar 2025
Antitumor activity observed with confirmed partial responses in 50% of patients. at highest dose tested to date, across multiple tumor types ... .
Edit

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

PR Newswire 17 Mar 2025
-       Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy.
Edit

Targeted alpha therapy: Breakthrough in treating refractory skin cancer

Science Daily 13 Mar 2025
Metastatic melanoma is the most aggressive form of skin cancer ... .
Edit

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire 10 Mar 2025
"I am happy to share these robust positive results from our Phase 2a RIVER trial in refractory ... About Refractory Chronic Cough (RCC) Refractory chronic cough has no approved therapies in the U.S.
Edit

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire 09 Mar 2025
ET, to share topline results from the Phase 2a RIVER trial of Haduvio in patients with refractory chronic cough ... About Refractory Chronic Cough (RCC) Refractory chronic cough has no approved therapies in the U.S.
Edit

ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors

PR Newswire 06 Mar 2025
IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy ... Tumor hypoxia (low oxygen levels) is an immunosuppressive factor in solid tumors ... Continue Reading. ImmunoGenesis ... Michael A ... 9k+ ... .
Edit

Chronic Refractory Gout Market Expected to rise, 2034 | Bristol Myers Squibb Company, Merck and ...

GetNews 04 Mar 2025
"Chronic Refractory Gout Market Expected to rise, 2034, DelveInsight" ... Some of the key highlights from the Chronic Refractory Gout Market Insights Report. ... Chronic Refractory Gout Overview ... Chronic Refractory Gout Epidemiology Insights.
  • 1
×